{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:00:55Z","timestamp":1793962855030,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the proposed name change for non-alcoholic fatty liver disease (NAFLD). This study aimed to investigate the association of cardiovascular disease risk with MASLD and NAFLD in patients who underwent clinically indicated coronary computed tomography angiography (CCTA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 2289 patients (60% men; mean age: 68 years) with no history of coronary artery disease who underwent CCTA. The steatotic liver was defined as a hepatic-to-spleen attenuation ratio of &lt;\u20091.0 on CT just before CCTA. MASLD is defined as the presence of hepatic steatosis along with at least one of the five cardiometabolic risk factors. Adverse CCTA findings were defined as obstructive and\/or high-risk plaques. Major adverse cardiac events (MACE) encompassed composite coronary events, including cardiovascular death, acute coronary syndrome, and late coronary revascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MASLD and NAFLD were identified in 415 (18%) and 368 (16%) patients, respectively. Adverse CCTA findings were observed in 40% and 38% of the patients with MASLD and with NAFLD, respectively. Adverse CCTA findings were significantly associated with MASLD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) but not NAFLD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.253). During a median follow-up of 4.4 years, 102 (4.4%) MACE were observed. MASLD was significantly associated with MACE (hazard ratio 1.82, 95% CI 1.18\u20132.83,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), while its association with NAFLD was not significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.070). By incorporating MASLD into a prediction model of MACE, including the risk score and adverse CCTA findings, global chi-squared values significantly increased from 87.0 to 94.1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with MASLD are likely to have a higher risk of cardiovascular disease than those with NAFLD. Concurrent assessment of MASLD during CCTA improves the identification of patients at a higher risk of cardiovascular disease among those with clinically indicated CCTA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02268-1","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T13:02:05Z","timestamp":1715346125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Takahiro","family":"Nishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2268_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"2268_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.14309\/ajg.0000000000000433","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Henry L. The impact of obesity and type 2 diabetes on chronic liver disease. Am J Gastroenterol. 2019;114:1714\u20135.","journal-title":"Am J Gastroenterol"},{"key":"2268_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2410","author":"R Medina-Santill\u00e1n","year":"2013","unstructured":"Medina-Santill\u00e1n R, L\u00f3pez-Vel\u00e1zquez JA, Ch\u00e1vez-Tapia N, Torres-Villalobos G, Uribe M. M\u00e9ndez-S\u00e1nchez N. hepatic manifestations of metabolic syndrome. Diabetes Metab Res Rev. 2013. https:\/\/doi.org\/10.1002\/dmrr.2410.","journal-title":"Diabetes Metab Res Rev"},{"key":"2268_CR4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/eurjpc\/zwab120","volume":"28","author":"K Ichikawa","year":"2022","unstructured":"Ichikawa K, Miyoshi T, Osawa K, Miki T, Toda H, Ejiri K, et al. Incremental prognostic value of non-alcoholic fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease. Eur J Prev Cardiol. 2022;28:2059\u201366.","journal-title":"Eur J Prev Cardiol"},{"key":"2268_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","volume":"29","author":"L Alon","year":"2022","unstructured":"Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:938\u201346.","journal-title":"Eur J Prev Cardiol"},{"key":"2268_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"2268_CR7","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa0806576","volume":"359","author":"JM Miller","year":"2008","unstructured":"Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359:2324\u201336.","journal-title":"N Engl J Med"},{"key":"2268_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jacc.2015.05.069","volume":"66","author":"S Motoyama","year":"2015","unstructured":"Motoyama S, Ito H, Sarai M, Kondo T, Kawai H, Nagahara Y, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol. 2015;66:337\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"2268_CR9","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.116.024360","volume":"135","author":"U Hoffmann","year":"2017","unstructured":"Hoffmann U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, et al. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (prospective Multicenter Imaging Study for evaluation of chest Pain). Circulation. 2017;135:2320\u201332.","journal-title":"Circulation"},{"key":"2268_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamacardio.2017.4973","volume":"3","author":"M Ferencik","year":"2018","unstructured":"Ferencik M, Mayrhofer T, Bittner DO, Emami H, Puchner SB, Lu MT, et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol. 2018;3:144\u201352.","journal-title":"JAMA Cardiol"},{"key":"2268_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.acra.2012.02.022","volume":"19","author":"I Zeb","year":"2012","unstructured":"Zeb I, Li D, Nasir K, Katz R, Larijani VN, Budoff MJ. Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad Radiol. 2012;19:811\u201318.","journal-title":"Acad Radiol"},{"key":"2268_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.01.032","volume":"283","author":"T Miki","year":"2019","unstructured":"Miki T, Miyoshi T, Kotani K, Kohno K, Asonuma H, Sakuragi S, et al. Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification: Subanalysis of a prospective multicenter study. Atherosclerosis. 2019;283:1\u20136.","journal-title":"Atherosclerosis"},{"key":"2268_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/clinchem\/hvab048","volume":"67","author":"M Sampson","year":"2021","unstructured":"Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A new equation based on the standard lipid panel for calculating small dense low-density lipoprotein-cholesterol and its use as a risk-enhancer test. Clin Chem. 2021;67:987\u201397.","journal-title":"Clin Chem"},{"key":"2268_CR14","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.5551\/jat.ER61960","volume":"30","author":"T Honda","year":"2023","unstructured":"Honda T, Chen S, Hata J, Yoshida D, Hirakawa Y, Furuta Y, et al. Development and validation of a risk prediction model for atherosclerotic cardiovascular disease in Japanese adults: the Hisayama study. J Atheroscler Thromb. 2023;30:1966\u20137.","journal-title":"J Atheroscler Thromb"},{"key":"2268_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijcard.2020.09.060","volume":"324","author":"K Suruga","year":"2021","unstructured":"Suruga K, Miyoshi T, Kotani K, Ichikawa K, Miki T, Osawa K, et al. Higher oxidized high-density lipoprotein to apolipoprotein A-I ratio is associated with high-risk coronary plaque characteristics determined by CT angiography. Int J Cardiol. 2021;324:193\u20138.","journal-title":"Int J Cardiol"},{"key":"2268_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jcmg.2020.01.022","volume":"13","author":"K Ichikawa","year":"2020","unstructured":"Ichikawa K, Miyoshi T, Osawa K, Miki T, Nakamura K, Ito H. Prognostic value of coronary computed tomographic angiography in patients with nonalcoholic fatty liver disease. JACC Cardiovasc Imaging. 2020;13:1628\u201330.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2268_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.mayocp.2013.12.015","volume":"89","author":"R Tota-Maharaj","year":"2014","unstructured":"Tota-Maharaj R, Blaha MJ, Zeb I, Katz R, Blankstein R, Blumenthal RS, et al. Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clin Proc. 2014;89:493\u2013503.","journal-title":"Mayo Clin Proc"},{"key":"2268_CR18","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASL-EASD-EASO","year":"2016","unstructured":"EASL-EASD-EASO. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol"},{"key":"2268_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcct.2020.11.002","volume":"15","author":"LJ Shaw","year":"2021","unstructured":"Shaw LJ, Blankstein R, Bax JJ, Ferencik M, Bittencourt MS, Min JK, et al. Society of Cardiovascular Computed Tomography \/ North American Society of Cardiovascular Imaging - Expert Consensus Document on coronary CT imaging of atherosclerotic plaque. J Cardiovasc Comput Tomogr. 2021;15:93\u2013109.","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2268_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jacc.2014.05.039","volume":"64","author":"SB Puchner","year":"2014","unstructured":"Puchner SB, Liu T, Mayrhofer T, Truong QA, Lee H, Fleg JL, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014;64:684\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"2268_CR21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/gut.2010.213553","volume":"59","author":"M Stepanova","year":"2010","unstructured":"Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410\u201315.","journal-title":"Gut"},{"key":"2268_CR22","doi-asserted-by":"publisher","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","volume":"97","author":"P Golabi","year":"2018","unstructured":"Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Med (Baltim). 2018;97:e0214.","journal-title":"Med (Baltim)"},{"key":"2268_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"2268_CR24","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, et al. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022;67:4919\u201328.","journal-title":"Dig Dis Sci"},{"key":"2268_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/liv.15508","volume":"43","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee JS, Lee HW, Kim BK, Park JY, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int. 2023;43:608\u201325.","journal-title":"Liver Int"},{"key":"2268_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fmed.2019.00202","volume":"6","author":"A Ismaiel","year":"2019","unstructured":"Ismaiel A, Dumitra\u015fcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med (Lausanne). 2019;6:202.","journal-title":"Front Med (Lausanne)"},{"key":"2268_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.31083\/j.rcm2203082","volume":"22","author":"R Galiero","year":"2021","unstructured":"Galiero R, Caturano A, Vetrano E, Cesaro A, Rinaldi L, Salvatore T, et al. Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med. 2021;22:755\u201368.","journal-title":"Rev Cardiovasc Med"},{"key":"2268_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138\u201353.","journal-title":"Gut"},{"key":"2268_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425\u201339.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2268_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1476-511X-13-100","volume":"13","author":"KE Corey","year":"2014","unstructured":"Corey KE, Misdraji J, Gelrud L, Zheng H, Chung RT, Krauss RM. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis. 2014;13:100.","journal-title":"Lipids Health Dis"},{"key":"2268_CR31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829\u201346.","journal-title":"J Hepatol"},{"key":"2268_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.gastrohep.2017.07.006","volume":"41","author":"J Ampuero","year":"2018","unstructured":"Ampuero J, S\u00e1nchez-Torrijos Y, Aguilera V, Bellido F, Romero-G\u00f3mez M. New therapeutic perspectives in non-alcoholic steatohepatitis. Gastroenterol Hepatol. 2018;41:128\u201342.","journal-title":"Gastroenterol Hepatol"},{"key":"2268_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367\u201378..e365; quiz e314-365.","journal-title":"Gastroenterology"},{"key":"2268_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver Disease in Primary Care and Endocrinology Clinical Settings: co-sponsored by the American Association for the study of Liver diseases (AASLD). Endocr Pract. 2022;28:528\u201362.","journal-title":"Endocr Pract"},{"key":"2268_CR35","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376:1916\u201322.","journal-title":"Lancet"},{"key":"2268_CR36","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","volume":"168","author":"MJ Tikkanen","year":"2013","unstructured":"Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168:3846\u201352.","journal-title":"Int J Cardiol"},{"key":"2268_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5114\/ceh.2022.120099","volume":"8","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Tahara T, Miura K, Lefor AK, Yamamoto H. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients. Clin Exp Hepatol. 2022;8:278\u201383.","journal-title":"Clin Exp Hepatol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02268-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T13:04:57Z","timestamp":1715346297000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02268-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2268"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02268-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Okayama University Hospital, and the study conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived owing to the study\u2019s retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}